Petrova M, Hurnikova Z, Laukova A, Dvoroznakova E
Microorganisms. 2024; 12(5).
PMID: 38792753
PMC: 11123709.
DOI: 10.3390/microorganisms12050923.
Skoufou M, Tsigalou C, Vradelis S, Bezirtzoglou E
Microorganisms. 2024; 12(1).
PMID: 38258020
PMC: 10818559.
DOI: 10.3390/microorganisms12010194.
Vargova M, Revajova V, Laukova A, Hurnikova Z, Dvoroznakova E
Life (Basel). 2023; 13(9).
PMID: 37763333
PMC: 10532878.
DOI: 10.3390/life13091930.
Robledo S, Perez-Silanes S, Fernandez-Rubio C, Poveda A, Monzote L, Gonzalez V
Pathogens. 2023; 12(7).
PMID: 37513786
PMC: 10383258.
DOI: 10.3390/pathogens12070939.
Ladjouzi R, Dussert E, Teiar R, Belguesmia Y, Drider D
Antibiotics (Basel). 2023; 12(7).
PMID: 37508284
PMC: 10376788.
DOI: 10.3390/antibiotics12071188.
Avidumicin, a novel cyclic bacteriocin, produced by Cutibacterium avidum shows anti-Cutibacterium acnes activity.
Koizumi J, Nakase K, Noguchi N, Nakaminami H
J Antibiot (Tokyo). 2023; 76(9):511-521.
PMID: 37264118
DOI: 10.1038/s41429-023-00635-w.
Advances in the preclinical characterization of the antimicrobial peptide AS-48.
Cebrian R, Martinez-Garcia M, Fernandez M, Garcia F, Martinez-Bueno M, Valdivia E
Front Microbiol. 2023; 14:1110360.
PMID: 36819031
PMC: 9936517.
DOI: 10.3389/fmicb.2023.1110360.
Identification of Aryl Polyamines Derivatives as Anti- Agents Targeting Iron Superoxide Dismutase.
Martin-Escolano R, Molina-Carreno D, Martin-Escolano J, Clares M, Galiana-Rosello C, Gonzalez-Garcia J
Pharmaceutics. 2023; 15(1).
PMID: 36678771
PMC: 9863987.
DOI: 10.3390/pharmaceutics15010140.
Embedding Biomimetic Magnetic Nanoparticles Coupled with Peptide AS-48 into PLGA to Treat Intracellular Pathogens.
Gaglio S, Jabalera Y, Montalban-Lopez M, Millan-Placer A, Lazaro-Callejon M, Maqueda M
Pharmaceutics. 2022; 14(12).
PMID: 36559238
PMC: 9785849.
DOI: 10.3390/pharmaceutics14122744.
Rationally Designed Minimal Bioactive Domains of AS-48 Bacteriocin Homologs Possess Potent Antileishmanial Properties.
Corman H, Ross J, Fields F, Shoue D, McDowell M, Lee S
Microbiol Spectr. 2022; 10(6):e0265822.
PMID: 36342284
PMC: 9769502.
DOI: 10.1128/spectrum.02658-22.
Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs.
Ezquerra-Aznarez J, Almeida Da Silva P, Ainsa J
Microorganisms. 2021; 9(11).
PMID: 34835459
PMC: 8622410.
DOI: 10.3390/microorganisms9112335.
Exploring the cytotoxic mechanisms of Pediocin PA-1 towards HeLa and HT29 cells by comparison to known bacteriocins: Microcin E492, enterocin heterodimer and Divercin V41.
Buss G, Wilson C
PLoS One. 2021; 16(9):e0251951.
PMID: 34473709
PMC: 8412286.
DOI: 10.1371/journal.pone.0251951.
Antimicrobial Activity of the Circular Bacteriocin AS-48 against Clinical Multidrug-Resistant .
Velazquez-Suarez C, Cebrian R, Gasca-Capote C, Sorlozano-Puerto A, Gutierrez-Fernandez J, Martinez-Bueno M
Antibiotics (Basel). 2021; 10(8).
PMID: 34438974
PMC: 8388780.
DOI: 10.3390/antibiotics10080925.
Library of Selenocyanate and Diselenide Derivatives as In Vivo Antichagasic Compounds Targeting Mitochondrion.
Martin-Escolano R, Molina-Carreno D, Plano D, Espuelas S, Rosales M, Moreno E
Pharmaceuticals (Basel). 2021; 14(5).
PMID: 34062791
PMC: 8147293.
DOI: 10.3390/ph14050419.
Selenium Derivatives as Promising Therapy for Chagas Disease: and Studies.
Martin-Escolano R, Etxebeste-Mitxeltorena M, Martin-Escolano J, Plano D, Rosales M, Espuelas S
ACS Infect Dis. 2021; 7(6):1727-1738.
PMID: 33871252
PMC: 8480776.
DOI: 10.1021/acsinfecdis.1c00048.
Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci.
Montalban-Lopez M, Cebrian R, Galera R, Mingorance L, Martin-Platero A, Valdivia E
Antibiotics (Basel). 2020; 9(9).
PMID: 32887311
PMC: 7558097.
DOI: 10.3390/antibiotics9090567.
Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations.
Soltani S, Hammami R, Cotter P, Rebuffat S, Ben Said L, Gaudreau H
FEMS Microbiol Rev. 2020; 45(1).
PMID: 32876664
PMC: 7794045.
DOI: 10.1093/femsre/fuaa039.
Genetic and Biochemical Evidence That Gr17 Produces a Novel and Sec-Dependent Bacteriocin, Enterocin Gr17.
Liu G, Wang Y, Li X, Hao X, Xu D, Zhou Y
Front Microbiol. 2019; 10:1806.
PMID: 31456764
PMC: 6700250.
DOI: 10.3389/fmicb.2019.01806.
Preclinical studies of toxicity and safety of the AS-48 bacteriocin.
Cebrian R, Rodriguez-Cabezas M, Martin-Escolano R, Rubino S, Garrido-Barros M, Montalban-Lopez M
J Adv Res. 2019; 20:129-139.
PMID: 31360546
PMC: 6637140.
DOI: 10.1016/j.jare.2019.06.003.
Insights into Chagas treatment based on the potential of bacteriocin AS-48.
Martin-Escolano R, Cebrian R, Martin-Escolano J, Rosales M, Maqueda M, Sanchez-Moreno M
Int J Parasitol Drugs Drug Resist. 2019; 10:1-8.
PMID: 30953804
PMC: 6447751.
DOI: 10.1016/j.ijpddr.2019.03.003.